| 751 | 25 | 15 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：探讨济生肾气汤加三七、鳖甲对四氯化碳(CCl4)诱导的肝纤维化大鼠模型的干预作用及具体机制。方法：将SPF级SD大鼠随机分为对照组、模型组、中药治疗(低、中、高剂量)组，模型组与中药治疗组采用腹腔注射40%CCl4橄榄油溶液，每周2次，持续8周的方法复制肝纤维化大鼠模型。造模成功后，各给药组分别灌胃相应药物，对照组及模型组予等体积蒸馏水灌胃，每天1次，治疗4周。末次灌胃结束后，对肝组织切片进行HE染色和Masson染色观察肝组织病理形态学，检测肝功能指标(ALT、AST);ELISA法测定转化生长因子β(TGF-β)、血管紧张素Ⅱ(Ang-Ⅱ)、壳多糖酶3样蛋白1(CHI3L1)、白介素-1(IL-1)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)含量；RT-PCR法测定Ⅰ型、Ⅲ型胶原蛋白(Col-Ⅰ、Col-Ⅲ)及TGF-β mRNA的表达水平。结果：HE和Masson染色显示模型组大鼠大量肝细胞炎症坏死，肝组织胶原纤维广泛增生，纤维间隔相互连接，假小叶形成，而中药各剂量治疗组大鼠的肝脏炎症及肝纤维化程度均较模型组减轻；与模型组比较，中药治疗组ALT、AST、TGF-β、Ang-Ⅱ、CHI3L1、IL-1、IL-6、TNF-α水平均下降，Col-Ⅰ、Col-Ⅲ、TGF-β mRNA表达均减少，其中以中药中、高剂量组效果最为明显(P<0.01)。结论：济生肾气汤加三七、鳖甲对CCl4诱导的大鼠肝纤维化具有明显的改善作用，其作用机制可能与下调血管紧张素转换酶(ACE)-血管紧张素Ⅱ(Ang-Ⅱ)-血管紧张素Ⅱ受体1(AT1R)信号通路相关基因表达，降低相关细胞因子水平、促进细胞外基质降解方面等有关。
Abstract：Objective:To investigate the interventional effect of Jisheng Shenqi Decoction plus Panax notoginseng and biometria on rat model of liver fibrosis induced by carbon tetrachloride(CCl4) and its specific mechanism. Methods: SPF SPRague-dawley rats were randomly divided into control group,model group,Chinese medicine treatment group(low,medium and high dose)group. The model group and Chinese medicine treatment group were intraperitoneally injected 40%CCl4 olive oil solution twice a week for 8 weeks to replicate the rat model of liver fibrosis. After modeling,each administration group was intragastrically given corresponding drugs,control group and model group were intragastrically given equal volume of distilled water,once a day,for 4 weeks. After the last intragastric administration,liver tissue sections were stained by HE and Masson to observe the pathological morphology of liver tissue and detect liver function(ALT and AST). The contents of transforming growth factorβ(TGF-β),angiotensin Ⅱ(Ang-Ⅱ),CHI3L1,INTERleukin-1(IL-1),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were determined by ELISA. The mRNA expression levels of Col-Ⅰ,Col-Ⅲ and TGF-β were determined by RT-PCR.Results:HE and Masson staining showed a large number of inflammatory necrosis of liver cells,extensive proliferation of collagen fibers,interconnective fibrous septa and formation of false lobules in liver tissue in model group. Compared with the model group,the levels of ALT,AST,TGF-β,Ang-Ⅱ,CHI3L1,IL-1,IL-6 and TNF-α were decreased in the TCM treatment group,while the mRNA expressions of Col-Ⅰ,Col-Ⅲ and TGF-β were decreased in the TCM treatment group,and the effect was most obvious in the medium-dose and high-dose groups(P<0.01).Conclusion:Jishengqi Decoction plus Panax notoginseng and bionjia can significantly improve CCl4-induced hepatic fibrosis in rats,and the mechanism may be related to down-regulation of angiotensin converting enzyme(ACE)-angiotensin Ⅱ(Ang-Ⅱ)-angiotensin Ⅱ receptor 1(AT1R)signaling pathway. Reduce the level of related cytokines and promote the degradation of extracellular matrix.
1 Taylor RS,Taylor RJ,Bayliss S,et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease:A systematic review and meta-analysis[J]. Gastroenterology, 2020,158(6):1611-1625.
2 Zhao Z,Lin CY,Cheng K. siRNA-and miRNA-based therapeutics for liver fibrosis[J]. Transl Res,2019,214:17-29.
3 Koaykul C,Kim MH,Kawahara Y,et al.Maintenance of neurogenic differentiation potential in passaged bone marrowderived human mesenchymal stem cells under simulated microgravity conditions[J]. Stem Cells Dev,2019,28(23):1552-1561.
4 张笑菲，高卓维，吕志平，等.丹参酮ⅡA抑制肝纤维化作用机制的研究进展[J].山东医药，2018,58(28):86-89.
5 Wu J,Pan L,Jin X,et al.The role of oxymatrine in regulating TGF-β1 in rats with hepatic fibrosis[J]. Acta cirurgica brasileira,2018,33(3):207-215.
6 顾宏图，桂红莲，徐列明，等.扶正化瘀片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的效果观察[J].临床肝胆病杂志，2021,37(2):309-313.
7 柯迎妹，江敏，周树波，等.兰坪虫草多糖组分分析及缓解小鼠肝纤维化研究[J].中国中药杂志，2020,45(21):5256-5264.
8 安祯祥，何远利，唐东昕，等.扶脾柔肝颗粒对肝纤维化模型大鼠的改善作用机制研究[J].中国药房，2021,32(21):2587-2592.
9 谢爱泽，吕超，石清兰，等.中医药防治肝纤维化机制的研究进展[J].中国医药导报，2020,17(17):34-37.
10 徐列明，刘平，沈锡中，等.肝纤维化中西医结合诊疗指南年版[J].中国中西医结合杂志，2019,39(11):1286-1295.
11 谢玉宝，萧焕明，施梅姐，等.肝纤维化的中医药治疗进展[J].时珍国医国药，2016,27(3):703-706.
12 刘莹，周晓玲，谢胜，等.济生肾气汤对干细胞移植后肝硬化大鼠干细胞归巢能力的影响[J].世界华人消化杂志，2015,23(7):1104-1109.
13 周晓玲，谢胜，陈峭，等.脐血干细胞移植结合补益肾气利湿法治疗、级肝硬化的疗效及机制探讨[J].实用临床医药杂志，2014,18(17):25-28.
14 刘彦明，何珊，曹越，等.GP73、AFP-L3、TIP30联合检测对乙型肝炎源性肝癌肝硬化的诊断价值[J].国际检验医学杂志，2018,39(22):2794-2800.
15 马莹莹，王麟，邬田港，等.壳多糖酶样蛋白在肝纤维化诊断中的研究进展[J].中华传染病杂志，2017,35(8):509-511.
16 Yan L,Deng Y,Zhou J,et al.Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection,2018,46(3):385-393.
17 Kjaergaard AD,Johansen JS,Bojesen SE,et al. Role of inflammatory marker YKL-40 in the diagnosis,prognosis and cause of cardiovascular and liver diseases[J].Crit Rev Clin Lab Sci,2016,53(6):396-408.
18 Huang H,Wu T,Mao J,et al. CHI3L1 is a liverenriched,noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis[J]. OMICS,2015,19(6):339-345.
19 Higashiyama M,Tomita K,Sugihara N,et al. Chitinase3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis[J]. Hepatol Res,2019,49(11):1316-1328.
20 Kumagai E,Mano Y,Yoshi S.et al.Serum YKL-10 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J].Sci Rep,2016,6(1):35282.
21 Myers RP,Pomier-Layrargues G,Kirsch R,et al.Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients[J].Hepatology(Baltimore,Md),2012,55(1):199-208.
22 李洪，严桐，朱珍，等.血清壳多糖酶样蛋白在慢性肝病显著纤维化和肝硬化中的诊断价值[J].中华肝脏病杂志，2018,26(5):337-341.
23 莫慧玲，卓传尚，吕旭江，等.壳多糖酶样蛋白在肝纤维化分期中的诊断价值[J].检验医学与临床，2020,17(7):914-917.
24 Rath T,Roderfeld M,Güler C,et al.YKL-40 and transient elastography,a powerful team to assess hepatic fibrosis[J].Scandinavian J Gastroenterol,2011,46(11):1369-1380.
25 陈旻湖.消化病学[M].北京：人民卫生出版社，2019:440-441.
26 熊莎，高建蓉，胡祖良，等.鳖甲提取物对抑制TGF-β诱导的大鼠肝星状细胞活化的影响[J].中国实验方剂学杂志，2017,23(19):155-159.
27 付玲珠，屠珏，凌云，等.鳖甲煎丸不同提取物对TGF-β1 诱导的HSC-T6细胞的影响[J].中华中医药杂志，2016,31(10):4295-4299.
28 吴朕，马微，臧成昊，等.三七皂苷R1保护四氯化碳诱导肝纤维化模型大鼠的作用[J].中国组织工程研究，2020,24(26):4213-4217.
29 王京凯，王艳春，王振宇.三七总皂苷对肝纤维化小鼠转化生长因子β_1及重组人SMAD家族成员3的调控作用研究[J].中国临床药理学杂志，2021,37(10):1163-1166.
30 张晓梅，焦占江，殷鹏，等.阻断RAAS不同环节对肝纤维化大鼠ACE2、AngⅡ、Ang1-7的影响[J].山东医药，2015,55(18):14-17.
31 Zhou J,Liang Y,Pan JX,et al. Protein extracts of Crassostrea gigas alleviate CCl_4-induced hepatic fibrosis in rats by reducing the expression of CTGF,TGF-β_1 and NF-κB in liver tissues[J].Molecul Med Rep,2014,3(5):127-136.
32 David G,Warnock.Prevention protection and the intrarenal renin-angio-tensin system[J].Semin Nephrol,2001,21(6):593-602.
33 杨悦杰，黄芬.肝星状细胞及相关细胞因子在肝纤维化形成中的作用[J].世界华人消化杂志，2007,(27):2885-2890.
34 Elswefy SE,Abdallah FR,Atteia HH,et al.Inflammation,oxidative stress and apoptosis cascade implications in bisphenol A-induced liver fibrosis in male rats[J].Int J Exp Pathol,2016,97(5):369-379.
35 Sferra R,Vetuschi A,Pompili S,et al.Expression of profibrotic and anti-fibrotic molecules in dimethylnitrosamine-induced hepatic fibrosis[J].Pathol Res Pract,2016,4(5):453-458.
36 Czaja MJ,Ding WX,Donohue TM,et al. Functions of autophagy in normal and diseased liver[J]. Autophagy,2013,9(8):1131-1158.
37 Kocabayoglu P,Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer[J].Front Biosci(Scholar edition),2013,5(2):217-230.
38 Li MR,Lu LG,Bu P,et al.Advances in research of epigenetic regulation in liver fibrosis[J].World Chin J Digestol,2013,21(32):3499-3508.
39 Rigolet A,Musset L,Dubourg O,et al. Inflammatory myopathies with anti-Ku antibodies:A prognosis dependent on associated lung disease[J]. Medicine,2012,91(2):95-102.
40 Wasmuth HE,Tacke F,Trautwein C. Chemokines in liver inflammation and fibrosis[J]. Semin Liver Dis,2020,30(3):215-225.
41 Liu J,Gong H,Zhang ZT,et al. Effect of angiotensinⅡand angiotensinⅡtype 1 receptor antagonist on the proliferation,contraction and collagen synthesis in rat hepatic stellate cells[J]. Chin Med J(Engl),2008,121(2):161-165.
42 胡泉东，李美静，陈琼锋，等.RAAS与肝纤维化的研究进展[J].中国细胞生物学学报，2017,39(2):250-254.
43 张晓平，张峰，陆茵，等.肝纤维化中肾素-血管紧张素的作用研究进展[J].中国药理学通报，2011,27(7):897-900.
44 陈阳，任思思，范妤，等.TGF-β1在肝纤维化发生发展中作用及机制的研究进展[J].山东医药，2021,61(28):110-114.
45 秦利静，张露，侯鹏，等.肝纤维化发病机制的研究进展[J].吉林医药学院学报，2021,42(5):369-371.
基本信息:
DOI：10.13210/j.cnki.jhmu.20220222.001
中图分类号:R285.5
引用信息:
[1]钟镇康,周晓玲,王月明,等.济生肾气汤加三七、鳖甲对CCl_4诱导肝纤维化大鼠模型的干预作用及机制[J].海南医学院学报,2022,28(10):742-749.DOI:10.13210/j.cnki.jhmu.20220222.001.
基金信息:
国家自然科学基金资助项目（81760855）; 柳州市肝病临床医学研究中心项目（2018AF10503）; 广西研究生教育创新计划资助项目（YCSY2020106）~~
2022-02-23
2022-02-23
2022-02-23